



November 2016

Enrolling Physicians for October 2016

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits	Tissue Procurement	Cancer Care Delivery Res.
Dr. Carlson (Mercy Spfld)		0.5250		0.5250		
Dr. Dalia (Mercy Joplin)			0.0125	0.0125		
Dr. Donegan (Mercy St. Louis)	1	1		1		
Dr. Ellis (OHA)					1	
Dr. Gillett (OHA)		0.125		0.125		
Dr. Hanson (Mercy St. Louis)	1	1.1		1.1		
Dr. Huq (Mercy St. Louis)	1	1	0.25	1.25		
Dr. Hu (Mercy St. Louis)		0.25		0.25		
Dr. Lobins (Cox)					1	
Dr. Shah (Freeman)		0.4625		0.4625		
Dr. Snider (Mercy Spfld)			0.0125	0.0125		1
Dr. Tiriveedhi (Mercy Spfld)		0.125		0.125		
Dr. Tummala (Mercy Spfld)	1	0.875	0.0125	0.8875		
TOTALS	4	5.4625	0.2875	5.75	2	1

October has been another slow month for CRO registrations and credits. We have 4 registrations and 5.75 credits for October. One fourth of the way through our grant year, CRO has earned 22.1375 credits. To be on track to meet NCI credit goal of 160 credits this year, we need to have earned 40 credits by 10/31/16. Please take every opportunity to enroll patients to a clinical trial. We did collect 2 of our 36 tissue + blood specimens for this grant year. Only 34 more to go.

Alliance A011401 Evaluating Role of Weight Loss

Alliance A011401, "Breast Cancer WEight Loss Study (BWEL Study)" is a randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment. Each enrollment is 1 treatment credit.

Cancer Care Delivery Research (CCDR) – CRO first enroller

CRO registered the first patient in the country to the S1415CD Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)) study! Congratulations to Judy Hancock our CCDR Coordinator who is working hard to develop our CCDR program. **S1415CD** evaluates a guideline based colony stimulating factor standing order intervention and determines the effectiveness of colony stimulating factor use as prophylaxis for patients receiving chemotherapy with intermediate risk for febrile neutropenia.

CRO Fall 2016 Steering Committee meeting

Shelly Cummings, Myriad Genetics spoke on "Personalizing Cancer Treatment with New, More Precise Clinical Diagnostic Tools". Attendees learned about new clinical diagnostics that are being discovered. Cummings, discussed the future of diagnostics; commitment to advancing science in both

hereditary cancer and personalized genomics; and, the most important topic... how patient outcomes will be impacted. Thirty investigators and research staff were in attendance.

TV & Radio 30-second Ads

CRO will soon be running ads on TV as well as radio. Below are the links to the three different ads which will begin airing when the national election is over. Our goal is to educate our community regarding clinical trials in hopes of increasing numbers of patients saying yes to clinical trial participation.

Cancer Research TV1-Rev1 https://secure-eb.cisco.com/1nO4L0WzQifWpeDYxb5Gwp9wFMdTyvHJam1rxWMbYC3nw2EJddR3PaRaWbg1i5C_rOXxKu9jkNVx6bta6IR-2gSFdeO6WCNz32mDnU7W6Wu0ivQ_C5YllgroqRuKroPUztFnh9ts4rr87s0_pn4zZ9EzRNrwPLesmV_LbcaPV0L5qjN35GD42N7rDIKr18QcTo8UX7p8chiGx9OnjNthjDGULjgxv17_NwsCJOxgbaSdLewbLbBBOQ5h55MEkWneDfWMFBn3gPC0RcgSOx3PTpPQRw7tUqmYj4vHfuGpt_uNkPM_RBd8MzR3ic_gRR56Ye/https%3A%2F%2Fyoutu.be%2Fd2hTsOVYizU

Cancer Research TV2-Rev1 https://secure-web.cisco.com/1oUOYoktD1ZOfRCm8qPrOFmkZRnWr76Svn9oyckqmBi8UCKOiiAAu7peQXyIEqokj_xaYLL41jsfUuIWffQGSzc4LzyJBgEgAfDI9gSRBlvCjPHAq_qRFgKA1Xhod5MEyn5UsmIKHBf0Wi_M6gpTUHsJM3YY_ydpbBwrO94s-0kxafF3CO7seyJMr70yNMsCnJS4YX7ni_UXLqUDUXLlyJJeAxH7JesCatlS6kz2iKqAEXDYIFY20-_GU5-hBTvZEq5P4rjmwm1-hi3egK5HxizbE4EK-Pw49L0q_4W428R5BkQj7DdVmO8-lazdfnSKYcC/https%3A%2F%2Fyoutu.be%2Fzs5e241aE3c

Cancer Research TV3-Rev1 https://secure-web.cisco.com/1FyHTp1GX0h7V3FVltLI1mMksdlyHYseW-o8pEdnu2Isastt1wtKh3K9sKlmo8RZTqNi4lGSV-70WvUaU8C1ALOSUfFxELvz_oDThrYNYF41RymbRkHTneKH5RCrnBg2Xj--ZI-o7Hb-1_sswD7A_NDg3EvEOTOyj3Uj-pyvSqKNdfestVpdN9TtQ5Vsr04fueQ-3I8nTRWThz3Pry7vAvzPSAi2S0fCrYxGIJrrGeMUhbYT3fEUM6n3fWO_VNljhKjWiHZth14Vx0mfY_KFcUG2KcpU_z30aev5TmFqRjpnj_ZRPBuoma4xTD1-K8w/https%3A%2F%2Fyoutu.be%2FV9rH27Vw-yU

ACTIVATION OF CIRB Protocols:

A011106 ALternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant Treatment (ALTERNATE) in postmenopausal women: A Phase III Study

SWOG S1507 A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies"

SWOG S1416 Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer"

APPROVAL OF Local Protocols:

SWOG S1206: A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer

Closure through Local IRB:

ECOG-ACRIN E1411 closed to accrual effective 9-9-16

CIRB Closures:

ALLIANCE A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation

- effective 10-21-2016 temporary suspension to new patient registration

SWOG S1400 Sub-Study D A Phase II Study of AZD4547 for Previously Treated FGFR-positive patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

- effective 10-14-2016 sub-study D temporary closed to accrual

ALLIANCE A021202 Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumor

- effective 10-21-2016 permanent closed